While the Trump administration touts its new drug discount platform, health policy analysts caution that the plan's benefits are narrow and may mislead consumers. We break down who might save—and the more reliable strategies for most Americans to cut prescription costs.
Healthcare analysts are raising red flags about the TrumpRx prescription drug platform, cautioning that its advertised savings may be misleading for insured patients and could lead to higher long-term costs.
Amgen's dual announcement of a dividend hike and participation in the TrumpRx discount drug platform presents investors with a complex calculus of near-term returns against long-term pricing and margin pressures, even as its pipeline advances.
The newly launched federal website TrumpRX aims to provide discounted cash prices on select brand-name drugs. While it offers a potential alternative for the uninsured, retirees are advised to carefully compare options with existing Medicare Part D plans.
The TrumpRx.gov website launches, offering cash-paying patients significant price cuts on over 40 drugs from major manufacturers, including high-profile weight-loss treatments.
Genentech CEO Ashley Magargee announced at the Reuters Pharma USA 2026 event that the company's influenza treatment Xofluza will be included in the upcoming tranche of medications on the government's TrumpRx.gov platform, as the firm expands its direct-to-patient sales model.
In a move that could expand access to lower-cost prescription drugs, pharmaceutical giants GSK and Amgen have agreed to list their medications on the Trump administration's TrumpRx platform, according to a Fox Business report.
Pharmaceutical giant Eli Lilly has entered the Trump administration's drug pricing program while announcing new research collaborations in autoimmune diseases and hearing loss. The company is concurrently advancing a multi-billion dollar U.S. manufacturing expansion to support its growing portfolio.
The Trump administration's prescription drug discount platform, TrumpRx.gov, is set to significantly expand its offerings with the addition of Amgen and GSK. The move brings the total number of discounted medications to 54, featuring steep price cuts on treatments for chronic conditions like arthritis, COPD, and psoriasis.
The Trump administration has launched a new website, TrumpRx.gov, aiming to connect consumers with discounted prescription drugs through coupons. While the President touted significant savings on medications for diabetes and fertility, questions remain about the platform's real-world impact and the scope of its partnerships with pharmaceutical companies.
The FDA has accepted and granted Priority Review for Pfizer's supplemental application for HYMPAVZI® (marstacimab), aiming to expand its use to treat younger hemophilia patients with and without inhibitors. A decision is expected by mid-2026.
Pfizer steps into the spotlight with a major role in a federal drug discount program and a regulatory boost for its hemophilia B therapy, as investors weigh near-term gains against longer-term performance.
The new Trump administration drug pricing platform, TrumpRx.gov, has drawn measured praise from some health industry CEOs for promoting price transparency, while analysts highlight its limited scope and potential political complications.
Cigna Group and the Federal Trade Commission have settled a high-profile lawsuit alleging anti-competitive practices in insulin pricing. The agreement, which requires no admission of wrongdoing from Cigna, is projected to save patients up to $7 billion over the next decade through reformed pharmacy benefit operations.
The Trump administration's newly launched prescription drug portal, TrumpRx.gov, is drawing scrutiny for its limited scope. While offering deep discounts on popular GLP-1 weight-loss medications, experts say the site's initial offerings fall short of a comprehensive solution for lowering drug costs for most Americans.
President Trump's recent campaign-style stops in Ohio and Kentucky touted an economic resurgence, but a closer examination of employment, wages, and inflation data reveals a more complex and less robust picture than the administration's narrative suggests.
Eli Lilly's new government pricing agreements for Zepbound and Mounjaro, coupled with strategic research partnerships, signal a pivotal shift in access and affordability for weight-loss medications, with potential ripple effects across the healthcare sector.
The White House's new 'TrumpRx' site offers discounted prices on select brand-name medications, yet analysts note limited impact for insured Americans and question the long-term strategy behind the agreements.
Your morning briefing: The search for Nancy Guthrie enters day six, the Trump administration's new prescription drug site goes live, Democrats push for ICE reforms, a deadly drug boat strike, and new revelations about Jeffrey Epstein's genetic pursuits.
President Trump unveiled TrumpRx.gov, a website offering discounted prescription medications directly from major pharmaceutical companies, framing it as a major step to alleviate cost-of-living pressures amid a heated election season.
